NCT04495478View on ClinicalTrials.gov

A Study of Ramucirumab (LY3009806) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

May 9, 2021

Study Completion Date

May 9, 2021

Conditions
Healthy
Interventions
DRUG

Ramucirumab - IV

Administered IV.

DRUG

Placebo - IV

Administered IV.

DRUG

Ramucirumab - SC

Administered SC.

DRUG

Placebo - SC

Administered SC.

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04495478 - A Study of Ramucirumab (LY3009806) in Healthy Participants | Biotech Hunter | Biotech Hunter